Real-life experience of abrocitinib for the treatment of female patients with persistent erythema of rosacea-Reference-Cited by-同舟云学术

Real-life experience of abrocitinib for the treatment of female patients with persistent erythema of rosacea

Published:2024-01 Issue: Volume:22 Page:
ISSN:1721-727X
Container-title:European Journal of Inflammation
language:en
Short-container-title:Eur J Inflamm

Author:

Teng Yan¹^ORCID,Zhong Huiting²^ORCID,Huang Youming¹,Tao Xiaohua¹,Fan Yibin¹,Yu Yong¹

Affiliation:

1. Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, China

2. Department of Dermatology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

Abstract

Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/1721727X241258794

Reference13 articles.

1. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROS acea CO nsensus ( ROSCO ) panel

2. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee

3. Successful treatment of chronic severe alopecia areata with abrocitinib

4. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis

5. Abrocitinib as a novel treatment for lichen sclerosus